Phacilitate Leaders World 

Technology Review: Gene Editing

Technology Review: Gene Editing

Edition, one of Phacilitate's technology review series examines gene editing approaches by viral and non-viral methods and where to access these services 

The manipulation of DNA and specific gene editing is one of the great scientific breakthroughs of our time. However, delivering gene modifying material into cells has posed some challenges, particularly when it comes to the large amounts required for advanced therapies and their required doses.

This report focuses on the various methods of delivery, their relative advantages and disadvantages, as well as the companies that are offering them.

Read more to understand:

  • Who’s offering non-viral approaches to cell engineering and how they are disrupting the cell membrane
  • The key characteristics and qualities of the four main vector types
  • A review of the organisations providing viral vectors for clinical and commercial needs
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK